GSK2186877A

**GSK2186877A** is an investigational GSK seasonal influenza vaccine candidate developed for active immunization against influenza, principally studied in older adults and also evaluated in young children. It was an adjuvanted influenza vaccine program referred to as **FluAS25**, designed to enhance vaccine-induced immune responses to influenza viral antigens, including hemagglutinin. The candidate was evaluated in completed Phase 3 studies for safety, immunogenicity, repeated annual vaccination, and prevention of laboratory-confirmed influenza in adults aged 65 years and older; it was also studied in a pediatric safety and immunogenicity trial. No marketed brand name or regulatory approval for GSK2186877A was identified. ([gsk-studyregister.com](https://www.gsk-studyregister.com/trials/106372))

Other names

FluAS25FluAS-25FluAS 25